First Patient Dosed in Phase 1 Trial Testing Small Molecule Treatment CA-4948 for AML
News
The first patient has been dosed in a Phase 1 trial investigating the small molecule CA-4948 as a treatment for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes ... Read more